Login to Your Account


AstraZeneca's CEO Exits as Firm Enters Patent Cliff Free Fall

By Nuala Moran
Staff Writer

Friday, April 27, 2012
LONDON – AstraZeneca plc is expected to boost deal-making and mergers and acquisitions activity after CEO David Brennan gave in to pressure from shareholders and agreed to resign his post.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription